This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Mallinckrodt Inks $1.3B Deal for Cadence

Stocks in this article: CADX

NEW YORK (The Deal) -- Dublin-based Mallinckrodt on Tuesday agreed to buy pain-fighting rival Cadence Pharmaceuticals  (CADX) for $1.3 billion to tap growing interest in the target's acetaminophen treatment to relieve pain.

Mallinckrodt, which operates out of Hazelwood, Mo., said it would pay $14 per Cadence share, a 26% premium to the target's Monday close.

"We have been impressed with the strong relationships that Cadence's commercial organizations have established with customers in the hospital channel and are excited by the opportunity to build on these relationships to expand our platform in this area," said Mallinckrodt CEO and president Mark Trudeau in a statement.

The buyer is working to beef up its specialty pharmaceutical portfolio after being spun off last June by Dublin medical devices manufacturer Covidien. Mallinckrodt hopes it got in early on the development of Cadence's Ofirmev injectable acetaminophen, its only product.

San Diego-based Cadence said the drug had estimated sales $110.5 million in 2013, more than double the $50.1 million in 2012. That number is expected to grow further since the drug only recently won approval for use in Canada.

Mallinckrodt also hopes the drug's position on the list of approved medications in 2,350 U.S. hospitals will give it leverage to sell its other treatments. The deal will immediately add to earnings, Mallinckrodt said.

Cadence had been seen as a potential acquisition target since it only offers a single product - most drug companies offer complete portfolios.

The deal is expected to close in March and Mallinckrodt said it would use loans from Deutsche Bank Securities and available cash for the purchase. Both boards are recommending the offer to shareholders and Mallinckrodt said it already has commitments from investors holding 13% of the target's stock.

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,959.44 +154.64 0.87%
S&P 500 2,078.54 +7.89 0.38%
NASDAQ 4,781.4240 +16.0440 0.34%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs